Skip to main content
OpenTrials

Clinical trial condition

Lentivirus Infections

Explore clinical trials studying Lentivirus Infections. Study availability and eligibility vary by location and protocol.

5,639 public trials 303 recruiting studies
Refine in advanced search Browse all conditions

Lentivirus Infections trial results

Active, Not Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Augusta, Georgia, United States
View all 108 locations
View Trial Details
Active, Not Recruiting

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

NCT06134362

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +13 more
Locations
  • GSK Investigational Site Almagro, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Francistown, Botswana
  • GSK Investigational Site Porto Alegre, Brazil
View all 33 locations
View Trial Details
Active, Not Recruiting

Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2

NCT06182241

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Cervical Cancer, +26 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Boston University Boston, Massachusetts, United States
  • MatCH Research Unit (MRU), a Division of the Wits Health Consortium, University of Witwatersrand Durban, KwaZulu-Natal, South Africa
View Trial Details
Active, Not Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

NCT04340596

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • Alabama CRS (Site ID# 31788) Birmingham, Alabama, United States
  • UCLA CARE Center CRS Los Angeles, California, United States
  • UCSD Antiviral Research Center CRS (Site ID: 701) San Diego, California, United States
  • University of California, San Fransisco HIV/AIDS CRS San Francisco, California, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

NCT06317051

Conditions
Blood-Borne Infections, Body Weight, Body Weight Changes, +16 more
Locations
  • Hospital Ramos Mejía Buenos Aires, Argentina
  • St Vincent's Hospital Sydney, New South Wales, Australia
  • Austin Health Melbourne, Victoria, Australia
  • CART-CRS Chennai, Tamil Nadu, India
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 85 locations
View Trial Details

Related conditions